Clinical Research

Coronavirus disease 2019 pandemic and allogeneic hematopoietic stem cell transplantation: a single center reappraisal

Caterina Giovanna Valentini1,*, Patrizia Chiusolo1,2,*, Maria Bianchi1, Elisabetta Metafuni1, Nicoletta Orlando1, Sabrina Giammarco1, Andrea Bacigalupo1,2, Simona Sica1,2,*, Luciana Teoﬁli1,2,*,**

1 Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
2 Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore, Rome, Italy

A B S T R A C T

Background: The coronavirus disease 2019 (COVID-19) pandemic has deeply modified the complex logistical process underlying allogeneic hematopoietic stem cell transplant practices. Aim: In light of these changes, the authors compared data relative to allogeneic transplants carried out from 2018 at their center before (n = 167) and during the pandemic (n = 45). Methods: The authors examined patient characteristics, donor and graft types, cell doses and main transplant outcomes. Moreover, the authors evaluated the rise of costs attributable to additional COVID-19-related procedures as well as the risk of adverse events these procedures conveyed to grafts or recipients. Results: Overall, the number of transplants did not decrease during the pandemic, whereas patients at high relapse risk were prioritized. Transplants were mainly from matched unrelated donors, with a significant decrease in haploidentical related donors. Moreover, the use of bone marrow as a graft for haploidentical transplant was almost abandoned. Cryopreservation was introduced for all related and unrelated apheresis products, with a median storage time of 20 days. Notably, transplant outcomes (engraftment, acute graft-versus-host disease and non-relapse mortality) with cryopreserved products were comparable to those with fresh products. Conclusion: Considering that the emergency situation may persist for months, cryopreserving allogeneic grafts can offer a lifesaving opportunity for patients whose allogeneic transplant cannot be postponed until after the end of the COVID-19 pandemic.

Introduction

The emergence of the coronavirus disease 2019 (COVID-19) pandemic has triggered an exceptional worldwide health care crisis. Italy was among the first nations in Europe where COVID-19 broke out. On January 27, 2020, the National Transplant Center in Italy issued the first warning about severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and hematopoietic stem cell (HSC) donation [1]. On February 24, 2020, the requirement for SARS-CoV-2 donor screening was introduced, first in COVID-19 high-risk districts and a few days later in the entire national area [2]. Since March 13, 2020, Italian transplant centers have been strongly recommended by the competent authority to start the conditioning regimen in recipients only after HSC products from either related or unrelated donors have been delivered and cryopreserved [3]. The same recommendations were issued by the European Society for Blood and Marrow Transplantation [4].

Altogether, the COVID-19 pandemic has deeply modified the complex allograft logistical process at multiple stages. On the one hand, it is conceivable that travel restrictions within and across countries, as well as the disease itself or the quarantine following SARS-CoV-2 exposure, could make it more difficult to access HSC donors, either related or unrelated. On the other hand, the graft collection that before the pandemic was strictly organized depending on the conditioning regimen of the recipient has been managed with a more flexible approach thanks to cryopreservation [5]. Because of concerns regarding the negative impact of freezing and thawing on the viability of HSCs, until now the authors have infused allogeneic HSC products soon after collection, whereas only a minimal proportion of grafts have been cryopreserved.

Because of all these considerations, the authors revised data to reflect the effect of the ongoing COVID-19 pandemic on their allogeneic transplant practices. To this end, the authors compared the number and types of allograft cryopreservation procedures carried out in the pre-
pandemic and pandemic periods. The authors examined cell doses and main transplant outcomes in patients receiving cryopreserved grafts. Moreover, the authors evaluated the rise of costs attributable to additional COVID-19-related procedures as well as the risk of adverse events these procedures conveyed to grafts or recipients.

Methods

Study population

All allogeneic HSC transplantations performed at the hematology transplant unit of Fondazione Policlinico A. Gemelli IRCCS of Rome (Italy) between January 1, 2018, and August 31, 2020, were retrospectively investigated. Transplants of cord blood units were not included in the study. The authors included in the COVID-19 period all transplants carried out after the first Italian transplant center warning (January 27, 2020) [1]. The ethics committee of Fondazione Policlinico A. Gemelli IRCCS approved the study (protocol 0030921/20).

Donor, recipient and graft variables

Donor variables included demographics, type of donation (related and unrelated), country of origin (if unrelated donors) and ABO match. Patient variables included demographics, diagnosis, status of disease at transplant (complete remission or not), disease risk index [6], hematopoietic cell transplantation comorbidity index (HCT-CI) [7], incidence of acute graft–versus-host disease (aGVHD) [8] and death. Graft variables were source (bone marrow [BM] or peripheral blood stem cells [PBSCs]), total nucleated cell (TNC) content, CD34+ cell content, CD3+ cell content and CD34+ cell viability assessed either fresh or frozen and post-freezing in cryopreserved products. Cell contents were expressed as cell dose (i.e., number of cells per kg of recipient body weight) and were obtained as previously reported [9].

Study endpoints and definitions

The authors compared characteristics of donors (demographics and country), recipients (demographics and disease-related data) and grafts (PBSCs or BM) in the different transplant periods (COVID-19 or pre-COVID-19). In transplants performed with fresh or cryopreserved grafts, the authors analyzed the following endpoints: TNC and CD34+ cell doses, cumulative incidence of neutrophil engraftment (i.e., day of achievement of an absolute neutrophil count \(\geq 0.5 \times 10^9/L\)), cumulative incidence of platelet engraftment (i.e., day of achievement of a platelet count \(\geq 20 \times 10^9/L\) unsupported by transfusion), reticulocyte recovery (i.e., reticulocyte count \(>2.7\%\)), cumulative incidence of aGVHD (grades II–IV) and non-relapse mortality (NRM) (i.e., death without prior relapse). Adverse events/reactions were defined according to Directive 2004/23/EC [10]. The cost evaluation was conducted considering direct and indirect costs for all activities in the cryopreservation process and calculating the mean values of procedures carried out along with COVID-19-related measures.

Statistical analysis

Continuous variables were expressed as median with relative interquartile range (IQR) and categorical variables as n (%). Univariate analysis for continuous and categorical variables was performed using the Mann–Whitney U test and Fisher exact test as appropriate. Cumulative incidence of neutrophil and platelet engraftment, reticulocyte recovery and aGVHD was calculated with death in the absence of investigated events as competing risk. NRM was calculated with relapse as a competing risk event. A comparison between curves was performed according to the Grey method and expressed as hazard ratio with 95% confidence interval (CI). \(P < 0.05\) was considered statistically significant. Analyses were performed using IBM SPSS Statistics 25.0 and NCSS 10 v 10.0.19.

Results

A total of 212 consecutive transplants from adult donors were included in the study. Although there was no difference regarding age, sex or diagnosis, patients transplanted during COVID-19 showed higher disease risk index and lower HCT-CI scores (Table 1). SARS-CoV-2 screening by polymerase chain reaction on nasopharyngeal swabs (with or without serology) was performed in all donors from March 2020 onward. Thirty-five (19 unrelated and 16 related) donors were screened. No positive donors were found.

Transplant distribution before and during the COVID-19 period

Graft and donor characteristics of transplants performed before and during the COVID-19 pandemic are shown in Table 2. Allogeneic HSC transplant activities at the authors’ center were not slowed by the pandemic, varying from a mean of 6.8 to 5.6 transplants per month (\(P = 0.7334\)). The authors observed a relative increase in transplants from unrelated donors (from 34.7% to 55.6%, \(P = 0.0155\)). Compared with the previous period, during the pandemic, the proportion of donations from European countries (96.0% versus 70.7%, \(P = 0.0103\)) increased. Overall, fewer transplants from haploidentical familial donors were performed (from 39.5% to 15.5%, \(P = 0.0025\). This resulted from the drastic decrease in BM harvesting procedures usually performed at the authors’ center in the pre-COVID-19 era (from 41.3% to 11.1% of all grafts, \(P = 0.0001\). In addition, haploidentical transplants before the pandemic were frequently carried out in patients with chronic myeloproliferative neoplasms, lymphoma or multiple myeloma. By contrast, during the pandemic, transplants in patients with chronic disease were postponed whenever possible (Table 1). As a result, six out of seven patients (85.7%) receiving a haploidentical transplant during the pandemic were affected by acute myeloid leukemia. In addition, PBSC instead of BM grafts were harvested from haploidentical donors to secure transplant in more urgent cases of patients with high-risk disease. Thirty-two out of 212 grafts underwent cryopreservation and storage before transplant, with a
median storage duration of 20 days (IQR, 12–26); all of these were PBSC grafts, and 31 had been collected during the pandemic (Table 2).

**Effect of cryopreservation on transplant outcomes**

The authors included in the analysis the 31 PBSC grafts cryopreserved from March 2020 onward and one related PBSC product cryopreserved in 2019 to bring forward upon donor request. Table 3 shows patient and graft characteristics of allogeneic transplants performed with fresh or cryopreserved products. Donor- and recipient-related variables were similar in fresh and cryopreserved products. Although patients transplanted with cryopreserved products seemed to be given slightly lower TNC doses than those infused with fresh products, they received similar CD34+ cell doses. Cryopreservation resulted in a slight loss of viable CD34+ cells, decreasing from 7.1 × 10^6 cells/kg (IQR, 5.4–8.8) to 6.2 × 10^6 cells/kg (IQR, 4.9–8.2) (P < 0.0001), as evaluated based on CD34+ cell viability at thawing. Despite this, fresh and cryopreserved grafts contained similar CD34+ cell doses. The estimated cumulative incidence of engraftment at day +30 in patients in the fresh and cryopreserved groups was 99.6% (95% CI, 80.0–96.9) and 96.1% (95% CI, 89.7–100) for neutrophils (P = 0.8393) and 76.4% (95% CI, 68.7–84.9) and 80.4% (95% CI, 67.6–95.7) for platelets (P = 0.5613), respectively. Similarly, there was no difference regarding reticulocyte recovery (P = 0.6101) (Figure 1A). Seventeen patients in the fresh group and five patients in the cryopreserved group developed grade II–IV aGVHD. The day +100 cumulative incidence of grade II–IV aGVHD in the fresh and cryopreserved groups was 19.5% (95% CI, 12.6–30.1) and 23.8% (95% CI, 9.7–58.5) (P = 0.3618), respectively (Figure 1B). Finally, the 1-year NRM was 16.1% (95% CI, 10.2–25.3) in patients receiving fresh grafts and 7.7% (95% CI, 2.0–29.8) in those receiving cryopreserved grafts (P = 0.5636) (Figure 1B).

**Adverse events**

During the pandemic, the authors recorded microbial culture positivity for a skin contaminant in one cryopreserved PBSC product. Among all products collected before the pandemic, only BM harvests (three grafts that were transfused fresh) had harbored similar microbial contamination. In addition, during the pandemic, the authors documented one adverse event due to a malfunction in controlled rate cooling during the freezing of one unrelated PBSC unit. This was the result of the failure of the thermocouple probe to correctly detect the cooling of the sample bag and caused an inability to retrieve the record of the temperature curve, whereas chamber cooling went on according to the defined program temperature curve. Therefore, the failure of the probe did not affect product viability. No adverse reactions related to the infusion of cryopreserved grafts were recorded.

**Additional costs**

Cryopreservation as a result of COVID-19-related measures resulted in additional costs due to the procedure itself, microbial cultures and viability tests performed on cryopreserved units before release. Table 4 shows direct costs the authors calculated based on mean technician hours worked and consumable and disposable

---

### Table 2

**Characteristics of donors and grafts.**

| Donors | Pre-COVID (n = 167) | Missing data | COVID n = 45 | Missing data | P value |
|--------|---------------------|--------------|--------------|--------------|---------|
| Age, years | 34.5 (26.2–45.1) | 6 (3.6) | 37 (30.3–47.3) | 2 (4.4) | 0.3185 |
| Male | 113 (68.9) | 3 (1.8) | 33 (72.7) | – | 0.2404 |
| Body weight (kg) | 75 (64–85) | 5 (2.9) | 76 (70.2–88.0) | 1 (2.2) | 0.2182 |
| Related | 109 (65.3) | – | 20 (44.4) | – | 0.0155 |
| Unrelated | 58 (34.7) | – | 25 (55.6) | – | 0.0258 |
| Unrelated donors | – | – | – | – | – |

### Table 3

**Donor, recipient and graft characteristics of transplants performed with fresh or cryopreserved PBSC products.**

| Fresh | Cryopreserved | P value |
|-------|--------------|---------|
| Patients | 106 | 32 | – |
| Age, years | 54.6 (43.5–60.6) | 51.5 (41.8–59.0) | 0.4492 |
| Male sex | 65 (61.3) | 16 (50.0) | 0.3071 |
| Diagnosis | | | |
| Acute myeloid leukemia | 40 (34.4) | 15 (46.9) | 0.5076 |
| Chronic myeloproliferative neoplasms | 20 (18.9) | 6 (18.7) | < 0.0001 |
| Acute lymphoblastic leukemia | 12 (11.3) | 7 (21.9) | 0.0155 |
| Myelodysplastic syndromes | 13 (12.3) | 2 (6.2) | 0.1859 |
| Hodgkin/non-Hodgkin lymphoma | 13 (12.3) | 2 (6.2) | < 0.0001 |
| Multiple myeloma/plasma cell leukemia | 2 (1.9) | 0 (0.0) | 0.4049 |
| Myeloablative conditioning regimen | 39 (36.8) | 9 (28.1) | 0.5613 |
| High/very high DRI score | 22 (20.7) | 14 (56.7) | 0.0022 |
| Complete remission | 58 (54.7) | 18 (56.2) | 0.0960 |
| HCT-CI score > 2 | 54 (50.9) | 7 (23.3) | 0.1585 |
| Donor age, years | 34.5 (24.9–45.7) | 39.2 (30.2–50.0) | 0.0960 |
| Female donor | 29 (27.9) | 11 (34.4) | 0.5101 |
| Haplodirectional related donor | 0 | 3 (9.4) | 0.115 |
| Major/bidirectional ABO mismatch | 31 (29.2) | 7 (21.9) | 0.7084 |
| TNC, 10^6 cells/kg | 8.7 (6.7–10.5) | 7.6 (6.3–8.9) | 0.2684 |
| CD34+ cells, 10^6 cells/kg | 7.1 (5.3–9.2) | 7.1 (5.4–8.8) | 0.9594 |
| CD3+ cells, 10^6 cells/kg | 207.0 (151.7–269.0) | 193.7 (144.0–276.4) | 0.8996 |
| Post-thaw CD34+ cells, 10^6 cells | – | 6.2 (4.9–8.2) | 0.1859 |

Data are expressed as n (%) or median (IQR).

* Missing data in five donors (4.7%).
** Missing data in one donor (3.0%).
*** Missing data in two donors (1.8%).

---

C.G. Valentini et al. / Cytotherapy 23 (2021) 635–640

637
Overall, every cryopreservation resulted in an additional cost of €382.62, corresponding to an overall expense of €12,244.

Discussion

The COVID-19 pandemic has caused the transplantation community to face exceptional challenges to avoid postponing this life-saving procedure while at the same time ensuring the absolute safety of donors and recipients. In this study, the authors reviewed data relative to allogeneic HSC transplantations performed at their center in the pandemic period to understand how their daily practices have changed to fulfill the requirements presented by the COVID-19 pandemic.

Despite the increased complexity of the whole process of donor procurement, workout and graft harvesting, the sprouting of the pandemic has not been associated with a decline in allogeneic transplants at the authors’ institution. The authors’ data emphasize that during the pandemic patients at higher relapse risk have been given

Figure 1. Transplant outcomes in patients receiving fresh (red lines) or cryopreserved (blue lines) products. (A) Cumulative incidence of neutrophil, platelet and reticulocyte engraftment. Reticulocyte engraftment is separately reported in total population and ABO matched/minor mismatched patients. (B) Cumulative incidence of grade II–IV acute GVHD and NRM.
The most remarkable change in the authors’ practices as a consequence of the COVID-19 pandemic has been to extend cryopreservation to allogeneic PBSC grafts. Until the pandemic, the authors cryopreserved only autologous products unless it was impossible to postpone donation for exceptional reasons related to donors or recipients. Cryopreservation was first introduced to prevent possible delays in unrelated product delivery, whereas it was rapidly adopted for related grafts. In fact, it has allowed more comfortable management of recipient hospital admissions as well as post-donation donor follow-up.

One of the main concerns related to cryopreservation is represented by the loss of viable cells due to unit processing or storage [16,17]. This risk may be exacerbated if products are cryopreserved at cell concentrations greater than 2 × 10^6 cells/mL or if they contain a large amount of granulocytes [18–20]. In this study, the authors confirmed that a portion of viable CD34+ cells are lost with cryopreservation. Nevertheless, it should be emphasized that the authors’ data were achieved using a single satellite vial, and the results were not confirmed using attached segments. In addition, the authors estimated CD34+ cell viability but not CD34+ cell potency since we did not carry out a colony-forming unit assay on the samples. Despite these limitations, the loss was negligible and did not significantly affect either the CD34+ cell dose or the hematopoietic recovery. Thus, the authors’ data confirm previous observations of allogeneic transplants performed with cryopreserved products, suggesting that this is a safe and feasible procedure [21–26]. In fact, previous studies comparing transplant outcomes in patients receiving fresh or cryopreserved grafts globally back cryopreservation in the allogeneic scenario [21–26]. Nonetheless, this might not be true in every clinical setting. In particular, Eapen et al. [27] have recently reported an increased incidence of graft failure and 1-year mortality in severe aplastic anemia patients receiving cryopreserved grafts. Given the short follow-up of patients transplanted with cryopreserved grafts at the authors’ center, they could explore only short-term transplant outcomes. Overall, the authors’ data do not show a difference regarding the incidence of engraftment, aGVHD and NRM in comparison with patients receiving fresh grafts, whereas longer follow-up is necessary to assess whether cryopreserved and fresh transplants elicit superimposable results with regard to chronic GVHD and disease-free and overall survival.

From an ethics perspective, the most important concern raised regarding cryopreservation is that, in exceptional circumstances related to the recipient (i.e., sudden worsening or death), the harvested product might not be transplanted [16,24]. In the present study, the authors found that all cryopreserved products were transfused, and the median storage duration was 20 days. This finding is in agreement with the high relapse risk of the authors’ patients and shows that, at least in our trial experience, graft collection is strictly organized to perform the transplant, whereas cryopreservation allows for flexible management of the recipient’s hospital admission. The policy of regularly cryopreserving allogeneic grafts undoubtedly results in additional expenses for the hospital. Considering the disease-related group reimbursement operated by the Italian National Health System for public hospitals, these costs can be considered marginal. Nonetheless, cryopreservation also implies additional risks related to unit processing, such as the risk of bag damage, possible microbial contamination and infusion reactions from dimethyl sulfoxide [16,24]. The authors did not observe adverse reactions among patients receiving cryopreserved products, but we experienced failure of the controlled rate cooling freezer during the processing of one unrelated PBSC unit. Fortunately, in the authors’ case, the failure did not affect product quality. Nevertheless, this episode suggests that both donors and recipients should be made aware of these cryopreservation drawbacks, possibly requiring arrangement of further donations. The authors also recorded microbial contamination of one PBSC product, likely occurring during processing. Notably, before the pandemic, the authors had to cope with similar problems only with BM grafts, whose contamination likely occurred during the harvesting procedure.

Conclusions

The authors’ experience with regard to allogeneic transplants with cryopreserved products suggests that this is a feasible and safe option, allowing compliance with all precautions imposed by the pandemic [24]. After the transient pandemic control during the
summer of 2020, several donor registries returned to normal procedures, and freezing products was no longer recommended considering several reports of cryopreserved products never being infused [17]. Presently, however, donors in many countries face a high risk of SARS-CoV-2 infection between workup and collection, and pre-planned cryopreservation is recommended [28]. Considering that this emergency situation may persist for months, cryopreserving allogeneic grafts might offer a lifesaving opportunity for patients whose allogeneic transplant cannot be postponed until after the end of the COVID-19 pandemic.

Declaration of Competing Interest

The authors have no commercial, proprietary or financial interest in the products or companies described in this article.

Funding

No funding was received.

Author Contributions

Conception and design of the study: CGV, PC, MB and LT. Acquisition of data: CGV, PC, MB, LT, NO, SG and EM. Analysis and interpretation of data: CGV, PC, MB, LT, NO, SG and EM. Drafting or revising the manuscript: CGV, PC, MB, LT, AB and SS. All authors have approved the final article.

Acknowledgments

The authors are in debt to Claudia Frau for her valuable work in managing relations with patients, donor registry and familial donors.

References

[1] http://www.trapianti.salute.gov.it/imgs/C_17_cntAvvisi_227_0_file.pdf (last accessed on November 16, 2020).
[2] http://www.trapianti.salute.gov.it/imgs/C_17_cntAvvisi_225_0_file.pdf (last accessed on November 16, 2020).
[3] http://www.trapianti.salute.gov.it/imgs/C_17_cntAvvisi_236_0_file.pdf (last accessed on November 16, 2020).
[4] Ljungman P, Mikulska M, de la Camara R, Basak GW, Chabannon C, Corbicagiu S, et al. Correction: The challenge of COVID-19 and hematopoietic cell transplantation: EBMTR recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy. Bone Marrow Transplant 2020:8:1.
[5] Algwaiz G, Aljurf M, Koh M, Horowitz MM, Ljungman P, Weisdorf D, et al. Real-World Experience on the Use of the Seattle Algorithm for Graft-versus-Host Disease Prophylaxis. Biol Blood Marrow Transplant 2020;26:2(1):e184–189. https://doi.org/10.1016/j.bbmt.2020.07.021.
[6] Armand P, Kim HT, Logan BR, Wang Z, Aleya EP, Kalaycio ME, et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood 2014;123(23):3664–71.
[7] Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005;106:2912–9.
[8] Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beaty T, Powis J, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995;15(6):825–8.
[9] Teofili L, Chiusolo P, Valentini CG, Metaffini E, Bellesi S, Orlando N, et al. Bone marrow haploidentical transplantation with post-transplantation cyclophosphamide: does graft cell content have an impact on main clinical outcomes? Cytotherapy 2020;22(3):158–65.
[10] https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=celex:32004L0023 (last accessed on November 16, 2020).
[11] Emami A, Javanmardi F, Pirbonyeh N, Akbari A. Prevalence of Underlying Diseases in Hospitalized Patients with COVID-19: a Systematic Review and Meta-Analysis. Arch Acad Emerg Med 2020;8:1;e35.
[12] Ueda Oshima M, Sandmaier BM, Petersdorf E, Flowers ME, Hill CR, Lee SJ, et al. Blood and marrow transplant during the emerging COVID-19 pandemic: the Seattle approach. Bone Marrow Transplant 2020;26:1;9–9. https://doi.org/10.1038/s41409-020-01068.
[13] Bashey A, Zhang MJ, McCurdy SR, St Martin A, Argall T, Anasetti C, et al. Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for–Cell Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide. J Clin Oncol 2017;10(35(26));3002–9.
[14] Fregni A, Labopin M, Bacigalupo A, Gbasss Z, Koc Y, Blaise D, et al. Bone marrow versus mobilized peripheral blood stem cells in haploidentical transplants using posttransplantation cyclophosphamide. Cancer 2018;124(7):1428–37.
[15] Mussetti A, De Philippis C, Carotti C, Bastos-Oreiro M, Cayojo J, Cieri N, et al. CD3+ graft cell count influence on chronic GVHD in allogeneic allogeneic transplantation using post-transplant cyclophosphamide. Bone Marrow Transplant 2018;53(12):1522–31.
[16] Dholaria B, Malku MMA, Arzt A, Savano BN. Securing the graft during pandemic: are we ready for cryopreservation for all? Biol Blood Marrow Transplant 2020;26(7):e145–6.
[17] https://wmda.info/wp-content/uploads/2020/07/20200611-SEAR-Rapid-Alert.pdf (last accessed on November 14, 2020).
[18] Felix OMWO, Tunes G, Ginani VC, Simões PC, Barros DP, Delbuono E, et al. The influence of cell concentration at cryopreservation on neutrophil engraftment after autologous peripheral blood stem cell transplantation. Hematol Transfur Cell Ther 2018;40(3):233–5.
[19] Castelhano MV, Reis-Alves SC, Vigorito AC, Rocha FF, Pereira-Cunha FG, De Souza CA, et al. Quantifying loss of CD34+ cells collected by apheresis after processing for freezing and post-thaw. Transfus Apher Sci 2013;48(2):241–6.
[20] Valentini CG, Bianchi M, Orlando N, Autore F, Iachininoto MG, Piccirillo N, et al. Graft Composition and Post-Thawing Cell Viability Influence the Hematopoietic Recovery in Autologous Hematopoietic Stem Cell Transplantation. J Stem Cell Res Ther 2017;7:370.
[21] Frey NV, Lazarus HM, Goldstein SC. Has allogeneic stem cell cryopreservation been given the ‘cold shoulder’? An analysis of the pros and cons of using frozen versus fresh stem cell products in allogeneic stem cell transplantation. Bone Marrow Transplant 2006;38(6):395–405. https://doi.org/10.1038/sj.bmt.1705462.
[22] Kim DH, Jamal N, Saragosa R, Loach D, Wright J, Gupta V, et al. Similar outcomes of cryopreserved allogeneic peripheral stem cells transplants (PBST) compared to fresh allografts. Biol Blood Marrow Transplant 2007;13(10):1233–43.
[23] Hamadani M, Zhang MJ, Tang XY, Fei M, Brunstein C, Chhabra S, et al. Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis. Biol Blood Marrow Transplant 2020;26(7):1312–7.
[24] Schmidt AH, Buk D, Platz A, van den Brink MRM. Cryopreservation for All Is No Option in Unrelated Stem Cell Transplantation. Comment on Dholaria B. Securing the graft during Pandemic. Are We Ready for Cryopreservation for All? Biol Blood Marrow Transplant 2020;26:e145–6.
[25] Purtill D, Antonenas V, Chiappini P, Tong D, OFlaherty E, Bajel A, et al. Variable CD34+ recovery of cryopreserved allogeneic HPC products: transplant implications during the COVID-19 pandemic. Blood Adv 2020;4(17):4147–50.
[26] Medd P, Nagra S, Hollyman D, Craddock C, Malladi R. Cryopreservation of allogeneic peripheral blood and marrow haploidentical transplant with post-transplantation cyclophosphamide: impact of donor leukocyte count on outcome. Bone Marrow Transplant 2020;8:1;e145–6.
[27] https://www.ebmt.org/sites/default/files/2020-11/EBMTRs20COVID-19%20guide-lines20v11.3.pdf (last accessed on November 14, 2020).